论文部分内容阅读
目的证实基因重组造血生长因子（ｒｈＨＧＦ）与化疗药物联合应用于急性髓性白血病（ＡＭＬ）的治疗是一种新的策略，可能有助于提高化疗药物对ＡＭＬ细胞的杀伤。方法采用对磺硝基四唑（ＩＮＴ）比色法，研究了１７例ＡＭＬ病人和８例正常人的骨髓细胞在体外对阿糖胞苷（Ａｒａ－Ｃ）的敏感性，分别观察了Ｇ－ＣＳＦ、ＧＭ－ＣＳＦ、ＩＬ－３３种细胞因子对其敏感性的影响。结果ＡＭＬ细胞分别对Ａｒａ－Ｃ敏感性存在着较大差异；Ｇ－ＣＳＦ，ＧＭ－ＣＳＦ，ＩＬ－３３种因子均能增加Ａｒａ－Ｃ对ＡＭＬ细胞的杀伤作用。结论３种细胞因子的作用有很大的异质性，３种ｒｈＨＧＦ均不能增加Ａｒａ－Ｃ对正常骨髓细胞的细胞毒性。
Objective To confirm the application of recombinant hematopoietic growth factor (rhHGF) combined with chemotherapeutic agents in the treatment of acute myeloid leukemia (AML) is a new strategy that may help to increase the killing of AML cells by chemotherapeutic agents. Methods The sensitivity of cytarabine (Ara-C) in bone marrow cells from 17 patients with AML and 8 normal controls was studied using sulfonitrazole (INT) colorimetry. G- Effects of CSF, GM-CSF and IL-33 Cytokines on Their Sensitivity. Results There was a significant difference in the sensitivity of Ara-C cells to Ara-C. G-CSF, GM-CSF, and IL-33 all increased the killing effect of Ara-C on AML cells. Conclusion The effects of the three cytokines are very heterogeneous, and all three rhHGF can not increase the cytotoxicity of Ara-C to normal bone marrow cells.